| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
14 |
| Employees |
117 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
200 |
| Cash Flow (TTM) (Millions $) |
215 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Merrimack Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapeutic agents for the treatment of cancer. The company was founded in 2000 and is headquartered in Cambridge, Massachusetts. It is focused on developing innovative therapies that can improve the lives of cancer patients, by disrupting tumor biology and delivering sustained clinical benefit.
Merrimack Pharmaceuticals develop drugs using a proprietary platform called the Merrimack Network Biology approach. This unique approach combines advanced biology and computational modeling to identify potential targets and pathways in the tumor microenvironment. The approach seeks to identify novel drug targets, better understand patient response, and develop more efficacious drug regimens.
The companyes pipeline is primarily focused on cancer indications, and it boasts several drug candidates in various stages of clinical development. Merrimackes flagship product candidate is MM-398, also known as enanoliposomal irinotecane or eOnivyde,e which was approved by the FDA for the treatment of metastatic pancreatic cancer in 201 It is the first and only FDA-approved therapy for patients with metastatic pancreatic cancer who have failed prior gemcitabine-based therapy.
The company other product candidates include MM-121, which targets HER3, and MM-141, which targets IGF-1R and HER Merrimackes candidates are designed to target multiple signal pathways, overriding resistance mechanisms that cancer cells can adopt, increasing the efficacy of the drugs and improving survival for patients.
Merrimack Pharmaceuticals has a team of experienced professionals, including scientists, clinicians, and business executives who bring expertise not only in oncology, but also in biotechnology, finance, and operations. The company has received multiple awards and has been recognized for its innovative approach to cancer drug development.
In recent years, Merrimack Pharmaceuticals conducted a strategic review of the company and concluded that the company would be better positioned to deliver value to shareholders through the strategic divestiture of its marketed product portfolio and development pipeline. In October 2017, Merrimack Pharmaceuticals announced the closure of their commercial operations to focus on oncology and clinical development of their promising pipeline.
In conclusion, Merrimack Pharmaceuticals Inc. has established itself as a leader in the pharmaceutical industry with its innovative approach to cancer drug development. With a diverse pipeline of products in clinical development for a variety of indications, Merrimack is poised to make significant strides in the treatment of cancer.
Company Address: One Broadway Cambridge 2142 MA
Company Phone Number: 720-8606 Stock Exchange / Ticker: NASDAQ MACK
|
%
0.14% 